PURPOSE: Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted a randomized phase II trial (TOWER [Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer]) to better define the ratio between benefits and risks with either treatment approach. PATIENTS AND METHODS: Patients were randomly assigned to two independent two-stage protocols of Tw (4 mg/m(2)/wk administered on days 1, 8, and 15) or Tc (1.25 mg/m(2)/d on days 1 to 5). We evaluated risk ratios (RRs) for the primary end point of clinical benefit (complete response, partial response, and stable disease), the duration of progression-free survival (PFS) and overall survival (OS), associated hazard ratios (HRs), and RRs of toxicity with 95% CIs. RESULTS: In total, 194 patients were randomly assigned at 54 centers to Tw (n = 97) or Tc (n = 97). Clinical benefit was observed in 36 of 76 (47%; 95% CI, 36% to 59%) Tw and 46 of 80 (58%; 95% CI, 46% to 68%) Tc patients (RR, 1.21; 95% CI, 0.90 to 1.64; P = .205). Patients in the Tw group had a slightly shorter PFS (HR, 1.29; 95% CI, 0.96 to 1.76) but similar OS (HR, 1.04; 95% CI, 0.74 to 1.45) compared with Tc. Tw was associated with significantly lower risks of anemia (RR, 0.35; 95% CI, 0.16 to 0.79), neutropenia (RR, 0.38; 95% CI, 0.23 to 0.65), and thrombocytopenia (RR, 0.23; 95% CI, 0.09 to 0.57). CONCLUSION: With regard to effectiveness in terms of response and PFS, Tc remains the standard of care in patients with platinum-resistant recurrent ovarian cancer. However, comparable OS rates and a favorable toxicity profile make Tw another viable treatment option in this setting.
RCT Entities:
PURPOSE: Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted a randomized phase II trial (TOWER [Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer]) to better define the ratio between benefits and risks with either treatment approach. PATIENTS AND METHODS: Patients were randomly assigned to two independent two-stage protocols of Tw (4 mg/m(2)/wk administered on days 1, 8, and 15) or Tc (1.25 mg/m(2)/d on days 1 to 5). We evaluated risk ratios (RRs) for the primary end point of clinical benefit (complete response, partial response, and stable disease), the duration of progression-free survival (PFS) and overall survival (OS), associated hazard ratios (HRs), and RRs of toxicity with 95% CIs. RESULTS: In total, 194 patients were randomly assigned at 54 centers to Tw (n = 97) or Tc (n = 97). Clinical benefit was observed in 36 of 76 (47%; 95% CI, 36% to 59%) Tw and 46 of 80 (58%; 95% CI, 46% to 68%) Tcpatients (RR, 1.21; 95% CI, 0.90 to 1.64; P = .205). Patients in the Tw group had a slightly shorter PFS (HR, 1.29; 95% CI, 0.96 to 1.76) but similar OS (HR, 1.04; 95% CI, 0.74 to 1.45) compared with Tc. Tw was associated with significantly lower risks of anemia (RR, 0.35; 95% CI, 0.16 to 0.79), neutropenia (RR, 0.38; 95% CI, 0.23 to 0.65), and thrombocytopenia (RR, 0.23; 95% CI, 0.09 to 0.57). CONCLUSION: With regard to effectiveness in terms of response and PFS, Tc remains the standard of care in patients with platinum-resistant recurrent ovarian cancer. However, comparable OS rates and a favorable toxicity profile make Tw another viable treatment option in this setting.
Authors: David M Hyman; Qin Zhou; Angela G Arnold; Rachel N Grisham; Alexia Iasonos; Noah D Kauff; David Spriggs Journal: Gynecol Oncol Date: 2011-08-19 Impact factor: 5.482
Authors: Jennifer R Diamond; Barbara Goff; Martin D Forster; Johanna C Bendell; Carolyn D Britten; Michael S Gordon; Hani Gabra; David M Waterhouse; Mark Poole; D Ross Camidge; Erika Hamilton; Kathleen M Moore Journal: Invest New Drugs Date: 2017-03-10 Impact factor: 3.850
Authors: Madeleine T King; Martin R Stockler; Rachel L O'Connell; Luke Buizen; Florence Joly; Anne Lanceley; Felix Hilpert; Aikou Okamoto; Eriko Aotani; Jane Bryce; Paul Donnellan; Amit Oza; Elisabeth Avall-Lundqvist; Jonathan S Berek; Jalid Sehouli; Amanda Feeney; Dominique Berton-Rigaud; Daniel S J Costa; Michael L Friedlander Journal: Qual Life Res Date: 2017-12-16 Impact factor: 4.147
Authors: Amit M Oza; Ursula A Matulonis; Angeles Alvarez Secord; John Nemunaitis; Lynda D Roman; Sarah P Blagden; Susana Banerjee; William P McGuire; Sharad Ghamande; Michael J Birrer; Gini F Fleming; Merry Jennifer Markham; Hal W Hirte; Diane M Provencher; Bristi Basu; Rebecca Kristeleit; Deborah K Armstrong; Benjamin Schwartz; Patricia Braly; Geoff D Hall; Kenneth P Nephew; Simone Jueliger; Aram Oganesian; Sue Naim; Yong Hao; Harold Keer; Mohammad Azab; Daniela Matei Journal: Clin Cancer Res Date: 2019-12-12 Impact factor: 12.531